Skip to content
approvedCognitive & Neuro

Actovegin

Also known as: Deproteinized hemodialysate of calf blood, Solcoseryl, Актовегин

Actovegin is a deproteinized hemodialysate derived from calf blood, containing a complex mixture of low-molecular-weight peptides, amino acids, oligosaccharides, nucleosides, and intermediate products of fat and carbohydrate metabolism. Approved in Russia, Austria, and numerous other countries (excluding the US and UK) for neurological and peripheral vascular conditions, it has been widely used for decades in the treatment of cognitive impairment, diabetic polyneuropathy, and stroke recovery. Its neuroprotective peptide fraction enhances cellular oxygen utilization and glucose uptake in neurons.

3 cited references·5 researched benefits

Quick Answer

Actovegin is a deproteinized calf blood hemodialysate containing low-molecular-weight peptides and bioactive compounds that enhance cellular oxygen and glucose metabolism. Approved in over 40 countries for cognitive impairment, stroke, and diabetic neuropathy, it improves neuronal energy metabolism and provides neuroprotection. The ARTEMIDA trial demonstrated significant cognitive benefits in post-stroke dementia. It is not FDA-approved and is banned by WADA in sports.

Key Facts

Mechanism
Actovegin's active fraction contains low-molecular-weight peptides (below 5 kDa) along with amino acid derivatives, oligosaccharides, and nucleoside metabolites. These components collectively enhance cellular energy metabolism through several mechanisms: activation of pyruvate dehydrogenase (increasing glucose oxidation), upregulation of glucose transporter proteins (GLUT1 and GLUT4) to increase cellular glucose uptake, enhancement of oxidative phosphorylation efficiency in mitochondria, and protection against oxidative stress through superoxide dismutase (SOD)-like activity. In neurons, this translates to improved energy supply under hypoxic or ischemic conditions, reduced vulnerability to excitotoxicity, and enhanced neuroplasticity. The peptide fraction also demonstrates insulin-like activity on intracellular glucose metabolism without binding to the insulin receptor.
Research Status
approved
Half-Life
Variable (complex mixture; elimination of active components occurs over several hours)
Molecular Formula
Complex mixture (MW < 5 kDa)
Primary Use
Cognitive & Neuro
Table of Contents

Benefits

  • Cognitive improvement after stroke — the ARTEMIDA trial (n=503) showed Actovegin significantly improved cognitive outcomes at 6 months post-stroke compared to placebo in patients developing post-stroke cognitive impairmentstrong
  • Diabetic polyneuropathy treatment — randomized controlled trials demonstrate significant improvements in nerve conduction velocity and reduction in neuropathic symptomsstrong
  • Enhanced cerebral metabolism — improves glucose and oxygen utilization in brain tissue under hypoxic conditions, supporting cognitive function in vascular dementiamoderate
  • Neuroprotection in ischemia — protects neurons from ischemic damage by maintaining mitochondrial function and reducing oxidative stress during energy deprivationmoderate
  • Wound healing acceleration — promotes tissue repair and angiogenesis, with established clinical use for wound and burn treatmentmoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intravenous800–2,000 mg dailyOnce daily for 10–20 daysUsed in acute neurological conditions such as ischemic stroke. Administered as a slow IV infusion in 200–300 mL saline. The ARTEMIDA trial used 2,000 mg IV daily for 20 days as the initial treatment phase.
Oral tablets600–1,800 mg daily200 mg three times daily, taken before mealsOral formulation used for maintenance therapy following IV course, or for chronic conditions such as cognitive impairment and diabetic polyneuropathy. Standard courses are 4–6 weeks.
Intramuscular injection200–400 mg dailyOnce dailyAlternative parenteral route when IV access is not available. Injections are limited to 5 mL per injection site.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Allergic reactions — hypersensitivity reactions including urticaria, flushing, and in rare cases anaphylaxis; contraindicated in patients with known calf protein allergyrare
  • Injection site pain — local pain and irritation at intramuscular or intravenous injection sitescommon
  • Gastrointestinal discomfort — nausea, stomach pain, or diarrhea with oral formulationscommon
  • Theoretical prion risk — as a bovine-derived biological product, theoretical concerns about BSE prion transmission exist, though manufacturing includes purification steps and no cases have been reportedserious

Frequently Asked Questions

Why is Actovegin not approved in the United States?
Actovegin has never been submitted for FDA approval, primarily for commercial and regulatory reasons rather than safety concerns. The US regulatory pathway for complex biological mixtures is more stringent than for single-molecule drugs, as the FDA requires precise characterization of active ingredients and their mechanisms. Additionally, as a bovine-derived product, it faces scrutiny regarding BSE (mad cow disease) prion transmission risk, even though no cases have been reported. The parent company (Nycomed/Takeda) appears to have made a business decision not to pursue the costly US approval process.
What was the ARTEMIDA trial and what did it show?
ARTEMIDA (A Randomized Trial of Efficacy, 12 Months International Double-blind Actovegin) was a landmark Phase III randomized, double-blind, placebo-controlled trial involving 503 patients across 33 sites in multiple countries. Patients who had experienced ischemic stroke and developed cognitive impairment were given either Actovegin (2,000 mg IV daily for 20 days, then 1,200 mg oral daily for 6 months) or placebo. The Actovegin group showed statistically significant improvement in cognitive function (ADAS-cog+ scores) at 6 months compared to placebo, with effects persisting at 12 months. Published in Stroke (2017), it remains the most rigorous clinical trial of Actovegin for cognitive outcomes.
Is Actovegin banned in sports?
Yes, Actovegin is prohibited by the World Anti-Doping Agency (WADA) under the category of blood-derived products. It has been the subject of several doping controversies in professional cycling and football. Despite being banned, some athletes have argued it should be permitted because its mechanism involves metabolic enhancement rather than direct performance-boosting effects. WADA classifies it as prohibited because it is an animal blood-derived preparation that could potentially enhance oxygen utilization and tissue repair.

References

  1. 1
    Actovegin in the treatment of patients with post-stroke cognitive impairment: ARTEMIDA (A Randomized Trial of Efficacy, 12 Months International Double-blind Actovegin)(2017)PubMed ↗
  2. 2
    Neuroprotective and neurotrophic effects of Actovegin in a rat model of transient global cerebral ischemia(2012)PubMed ↗
  3. 3
    Efficacy and safety of Actovegin in the management of diabetic polyneuropathy: a randomized controlled trial(2009)PubMed ↗

Latest Research

Last updated: 2026-02-19